ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Observational Study"

  • Abstract Number: 0729 • ACR Convergence 2021

    A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects

    Ismail Simsek1, Christopher Swearingen1, Heli Ghandehari1, Sarah Kennedy2, Jeyanesh Tambiah1, Yusuf Yazici3 and Nebojsa Skrepnik4, 1Biosplice Therapeutics, Inc., San Diego, CA, 2Biosplice Therapeutics, Inc, San Diego, CA, 3New York University School of Medicine, La Jolla, CA, 4Tucson Orthopaedic Institute, Tucson

    Background/Purpose: Lorecivivint (LOR), a novel intra-articular (IA) CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways, is in development as a knee osteoarthritis (OA) treatment. To…
  • Abstract Number: 1202 • ACR Convergence 2021

    Widespread but Not Regional Non-articular Pain Influences Patient and Rheumatologist Reported Change in Clinical Disease Activity Index Scores over Time – Implications for Using Patient Ratings in Telehealth – a Study from the Canadian Early Arthritis Cohort

    Vivian Bykerk1, Orit Schieir2, Marie-France Valois3, Glen Hazlewood4, Gilles Boire5, Carol Hitchon6, Louis Bessette7, Diane Tin8, Edward Keystone9, Carter Thorne8, Janet Pope10 and Susan Bartlett3, 1Hospital for Special Surgery, New York, NY, 2Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 3McGill University, Montréal, QC, Canada, 4University of Calgary, Calgary, AB, Canada, 5Universite de Sherbrooke, Sherbrooke, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 8Southlake Regional Health Centre, Newmarket, ON, Canada, 9Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 10University of Western Ontario, London, ON, Canada

    Background/Purpose: During the COVID pandemic assessments of RA disease activity (DA) have relied on virtual assessments by patient report. It is unknown whether non-articular pain…
  • Abstract Number: 1738 • ACR Convergence 2021

    Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study

    Uta Kiltz1, Jan Brandt-Jrgens2, Peter Kästner3, Elke Riechers4, Daniel Peterlik5, Annika Boas6 and Hans-Peter Tony7, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Rheumatologische Schwerpunktpraxis, Berlin, Germany, 3Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, 4Department for Rheumatology and Immunology, Hannover Medical University, Hannover, 5Novartis Pharma GmbH, Nürnberg, Germany, 6Novartis Pharma GmbH, Nuernberg, Germany, 7Universitätsklinikum Würzburg, Wuerzburg, Germany

    Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology